Table of Contents
ISRN Nephrology
Volume 2014 (2014), Article ID 479645, 7 pages
Research Article

Angiotensin Type-1 Receptor Blockade May Not Protect Kidney against Cisplatin-Induced Nephrotoxicity in Rats

1Water and Electrolytes Research Center, Isfahan University of Medical Sciences, Isfahan 81745, Iran
2Department of Biology, Falavarjan Branch, Islamic Azad University, Isfahan 84515, Iran
3Department of Physiology, Isfahan University of Medical Sciences, Isfahan 81745, Iran
4Isfahan MN Institute of Basic and Applied Sciences Research, Isfahan 81546, Iran
5Department of Clinical Pathology, Isfahan University of Medical Sciences, Isfahan 81745, Iran
6Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan 81745, Iran

Received 25 December 2013; Accepted 19 February 2014; Published 16 March 2014

Academic Editors: C. Escobar, L. Truong, and A. H. Tzamaloukas

Copyright © 2014 Roya Rastghalam et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. Cisplatin (CDDP) is an anticancer drug, which is accompanied with major side effects including nephrotoxicity. We tested two doses of losartan (10 and 20 mg/kg/day) against nephrotoxicity in a rat model treated with daily administration of CDDP (2.5 mg/kg/day). Methods. Five groups of rats were examined. Groups 1 and 2 received losartan 10 and 20 mg/kg/day, i.p, for a period of 10 days. Group 3 received saline for 10 days, but from day 3 the animals received CDDP (2.5 mg/kg/day, i.p) for the next seven days. Groups 4 and 5 received treatment regimen the same as groups 1 and 2, but from day 3 they also received CDDP for the next seven days. At the end of the experiment, blood samples were obtained and the kidneys were removed to undergo pathological investigation and to obtain supernatant from homogenized tissue. Results. CDDP induced nephrotoxicity, but the serum levels of creatinine and blood urea nitrogen were not attenuated by losartan. The pathological findings confirmed that losartan did not have nephroprotective effect in this experimental model. Conclusion. According to the findings, losartan could not improve renal function impaired by toxicity induced by continuous doses of CDDP, and also it worsened the renal failure.